Clinical Trial Tests NR Effect on Sleep Quality

The NADream trial evaluated the effect of nicotinamide riboside on objective sleep quality.

Nicotinamide adenine dinucleotide (NAD+) is a crucial coenzyme found in every living cell, where it serves as a metabolic driver and supports cellular maintenance. Recently, researchers in metabolic health and chronobiology (the study of biological clocks) have focused on the relationship between NAD+ levels and circadian rhythms. The body's internal clock, which regulates the sleep-wake cycle, is coupled with cellular metabolism through NAD+-dependent enzymes called sirtuins. Sirtuins act as metabolic sensors, using NAD+ to help align cellular activity with the external day-night cycle.

As we age, our systemic and tissue-specific NAD+ levels progressively decline, which can lead to mitochondrial dysfunction and disrupted sleep patterns. This age-related depletion is linked to poor sleep architecture, such as reduced slow-wave (deep) sleep and frequent nighttime awakenings. Exploring ways to support NAD+ levels, such as through supervised NAD+ therapy options, has become an active area of research for healthy aging and sleep restoration.

Understanding the Connection Between NAD+ and Sleep Architecture

The NADream clinical trial (NCT06893201) was launched to evaluate whether oral supplementation with nicotinamide riboside (NR), a natural NAD+ precursor, can improve sleep quality and mitochondrial efficiency in middle-aged adults. The double-blind, placebo-controlled study enrolled 120 healthy participants aged 45 to 65 who reported mild to moderate sleep disturbances. To ensure clear results, the researchers excluded individuals with diagnosed sleep disorders like clinical sleep apnea, shift workers, and those taking high-dose NAD+ supplements.

The treatment protocol randomized participants to receive either a daily dose of 2,000 mg of oral NR (administered as 1,000 mg twice daily) or a matching placebo for eight weeks. The researchers tracked how effectively oral NR could raise systemic NAD+ levels and whether this elevation translated to improvements in deep sleep architecture and cellular energy production. The findings are expected to provide key insights into how targeting cellular metabolism can improve sleep quality in aging populations.

The NADream Trial Design and Methodology

To objectively evaluate the impact of NR on sleep, the NADream trial used a comprehensive suite of advanced physiological monitoring and biochemical assessment tools. The primary endpoint of the study was the change in electrophysiological slow-wave activity (SWA), which is measured by electroencephalography (EEG) during polysomnography (PSG) from baseline to week eight. Polysomnography is the clinical gold standard in sleep medicine, providing continuous recordings of brain activity, eye movements, muscle tone, and heart rate during sleep.

By analyzing SWA, the research team aimed to determine whether NR supplementation could influence the depth and intensity of non-rapid eye movement (NREM) sleep, which is critical for cellular repair and memory consolidation. The trial also tracked several secondary parameters, including slow-wave energy (SWE), sleep efficiency, and wake after sleep onset (WASO) to build a detailed profile of sleep quality.

In addition to laboratory sleep studies, the trial incorporated multi-day, non-invasive tracking in participants' home environments. Participants wore Axivity actigraphy devices to track daily movement and rest patterns, and used Somnofy, a non-invasive sleep assistant, to monitor sleep cycles. These objective measures were paired with validated questionnaires, including the Pittsburgh Sleep Quality Index (PSQI) and the Chalder Fatigue Questionnaire (CFQ), to capture patient-reported sleepiness and energy levels.

Advanced Monitoring: Polysomnography and Biomarkers

To measure systemic physiological changes, the researchers collected blood samples to evaluate inflammation and oxidative stress biomarkers, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha). The NAD+ metabolome was quantified in blood samples using liquid chromatography-mass spectrometry (LC-MS) metabolomics. This allowed the research team to correlate the exact degree of systemic NAD+ elevation with changes in deep sleep slow-wave activity and sleep quality.

Furthermore, muscle biopsies were performed on a subset of participants to directly measure mitochondrial respiration and muscle NAD+ content. These tissue-specific measurements are essential for confirming whether oral NR supplementation improves mitochondrial efficiency and energy production in peripheral tissues. By combining sleep tracking, blood biomarkers, and muscle tissue analysis, the NADream trial represents one of the most comprehensive human studies on NAD+ precursors to date.

Understanding these cellular mechanisms is key to developing targeted therapies for age-related sleep issues. If the trial shows that NR safely supports deep sleep, it could establish a clear clinical link between metabolic health and sleep quality. This could lead to new, non-pharmacological interventions for sleep disorders in middle-aged and older adults. To see if you are a candidate for metabolic wellness programs, you can check if you qualify online.

Potential Implications for Middle-Aged Adults and Mitochondrial Health

Maintaining mitochondrial health is essential for healthy aging, as mitochondria are the powerhouses of our cells. Since sleep and cellular repair are closely linked, improving sleep quality may directly support mitochondrial function and reduce oxidative stress. For middle-aged adults, who often experience both declining NAD+ levels and poorer sleep quality, NR supplementation could offer a dual benefit, protecting both cognitive function and physical vitality.

Chronic sleep deprivation is a major risk factor for cardiometabolic diseases, including insulin resistance, obesity, and cardiovascular disease. By supporting the body's natural circadian rhythms and enhancing slow-wave sleep, NR may help mitigate these cardiometabolic risks. While clinical trials use high research doses, the data will help healthcare providers design safe, effective wellness programs for patients seeking to optimize their metabolic and sleep health.

As research into cellular health grows, clinical interest in metabolic support options remains high. For individuals interested in exploring supervised wellness options, you can view current pricing for diagnostic assessments and metabolic health programs online. Working with a qualified doctor is the best way to determine if NAD+ precursors are appropriate for your individual health goals.

Future Outlook: From Healthy Aging to Neurodegenerative Research

Establishing how NAD+ precursors affect sleep architecture in a healthy, middle-aged population provides researchers with crucial baseline data. If oral nicotinamide riboside is shown to safely support sleep quality and mitochondrial function, it could lead to targeted therapies for neurodegenerative diseases. Conditions like Alzheimer's and Parkinson's are heavily linked to mitochondrial decay and severe sleep disruptions, which can worsen cognitive decline.

The ability to monitor sleep non-invasively using actigraphy and Somnofy in large trials will facilitate more comprehensive, long-term research. As the NADream trial results are finalized, they will help transition NAD+ research from animal models to evidence-based human medicine. Ultimately, these findings will shape how we approach healthy aging, sleep restoration, and metabolic wellness in the future.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.